v3.26.1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
3 Months Ended
Apr. 14, 2026
May 15, 2025
May 05, 2025
Jun. 30, 2026
Jun. 30, 2025
Mar. 31, 2026
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Number of shares issued for cash         51,203  
Value of shares issued for cash         $ 395,474  
Value of common stock issued in exercise of warrants         3,949,730  
Stock-based compensation       $ 67,012 125,127  
Stock-based compensation expense       0 0  
President [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Number of stock options issued 20,426          
Exercise price of options issued $ 0.56          
Options vesting period 48 months          
Options expiration period 10 years          
Employees [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock-based compensation       41,700 61,701  
Unamortized stock option expense       109,943    
Non-Employees [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock-based compensation       25,312 $ 63,416  
Unamortized stock option expense       $ 141,828    
Share-Based Payment Arrangement, Option [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Number of options outstanding       133,917   134,397
Number of stock options issued       20,426 0  
weighted average exercise price of options outstanding       $ 3.18   $ 3.72
Intrinsic value of options outstanding       $ 0    
Exercise price of options issued       $ 0.56    
Stock-based compensation       $ 67,012 $ 125,127  
Unamortized stock option expense       $ 251,771    
Weighted average vesting period for unamortized stock compensation       3 years 5 months 19 days    
Series C Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Common stock issuable upon conversion   1        
Series D Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Conversion price   $ 10.00        
Preferred stock, stated value   $ 1,000        
Series C-1 Convertible Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Common stock issuable upon conversion   1        
Phytanix Bio [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock-based compensation   $ 10        
Phytanix Bio [Member] | Series C Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Number of shares issued in merger         5,705  
Phytanix Bio [Member] | Series C-1 Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Number of shares issued in merger         950,000  
Phytanix Bio [Member] | Series D Preferred Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Number of shares issued in merger         20,000  
Common Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Number of shares issued for cash         51,203  
Value of shares issued for cash         $ 5  
Common stock issued in exercise of warrants         1,145,928  
Value of common stock issued in exercise of warrants         $ 115  
Number of reverse split shares     3,920      
Common Stock [Member] | Phytanix Bio [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Number of shares issued in merger         117,690  
Warrant [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Common stock issued in exercise of warrants         1,145,928  
Value of common stock issued in exercise of warrants         $ 3,949,730  
Shares issuable under warrants outstanding       74,506   3,243,549
Warrant exercise price       $ 0.84   $ 267.57
Warrants outstanding, intrinsic value       $ 0